Contemporary Methods for Predicting Acute Kidney Injury After Coronary Intervention.

Autor:	Uzendu A; Cardiovascular Outcomes, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri Kansas City, Kansas City, Missouri, USA. Electronic address: uzendu14@gmail.com., Kennedy K; Cardiovascular Outcomes, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri Kansas City, Kansas City, Missouri, USA., Chertow G; Department of Medicine, Stanford University, Stanford, California, USA., Amin AP; Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA., Giri JS; Penn Center for Quality, Outcomes, and Evaluative Research, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA., Rymer JA; Department of Medicine, Duke University, Durham, North Carolina, USA., Bangalore S; Department of Medicine, New York University Langone, New York, New York, USA., Lavin K; Department of Science and Quality, American College of Cardiology, Washington, DC, USA., Anderson C; Department of Science and Quality, American College of Cardiology, Washington, DC, USA., Wang TY; Department of Medicine, Duke University, Durham, North Carolina, USA., Curtis JP; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Spertus JA; Cardiovascular Outcomes, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri Kansas City, Kansas City, Missouri, USA.
Jazyk:	angličtina
Zdroj:	JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2023 Sep 25; Vol. 16 (18), pp. 2294-2305.
DOI:	10.1016/j.jcin.2023.07.041
Abstrakt:	Background: Acute kidney injury (AKI) is the most common complication after percutaneous coronary intervention (PCI). Accurately estimating patients' risks not only creates a means of benchmarking performance but can also be used prospectively to inform practice. Objectives: The authors sought to update the 2014 National Cardiovascular Data Registry (NCDR) AKI risk model to provide contemporary estimates of AKI risk after PCI to further improve care. Methods: Using the NCDR CathPCI Registry, we identified all 2020 PCIs, excluding those on dialysis or lacking postprocedural creatinine. The cohort was randomly split into a 70% derivation cohort and a 30% validation cohort, and logistic regression models were built to predict AKI (an absolute increase of 0.3 mg/dL in creatinine or a 50% increase from preprocedure baseline) and AKI requiring dialysis. Bedside risk scores were created to facilitate prospective use in clinical care, along with threshold contrast doses to reduce AKI. We tested model calibration and discrimination in the validation cohort. Results: Among 455,806 PCI procedures, the median age was 67 years (IQR: 58.0-75.0 years), 68.8% were men, and 86.8% were White. The incidence of AKI and new dialysis was 7.2% and 0.7%, respectively. Baseline renal function and variables associated with clinical instability were the strongest predictors of AKI. The final AKI model included 13 variables, with a C-statistic of 0.798 and excellent calibration (intercept = -0.03 and slope = 0.97) in the validation cohort. Conclusions: The updated NCDR AKI risk model further refines AKI prediction after PCI, facilitating enhanced clinical care, benchmarking, and quality improvement. Competing Interests: Funding Support and Author Disclosures Dr Anezi Uzendu is supported by the National Heart, Lung and Blood Institutes of Health under Award Number 5T32H110837. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Chertow serves on the Board of Directors of Satellite Healthcare, a nonprofit dialysis provider; has served as a steering committee member or chair for clinical trials sponsored by Akebia, AstraZeneca, CSL Behring, Gilead, Sanifit, and Vertex; has served as an advisor to Ardelyx, Durect, Eliaz Therapeutics, Miromatrix, Outset, Reata, Renibus, and Unicycive; and has served as a Data Safety and Monitoring Board member or chair for trials sponsored by Bayer, Gilead, Mineralys, Palladio, and ReCor. Dr Giri has received research funds to his institution; and has served on advisory boards for Boston Scientific, Abiomed, Abbott Vascular, Inari Medical, Biosense Webster, and Recor Medical. Dr Rymer has served on the advisory board for Chiesi; has received a research grant from Chiesi; and receives research funding from Idorsia, Pfizer, and Abbott. Dr Bangalore discloses has served on the advisory board for Abbott Vascular, Boston Scientific, Amgen, Pfizer, Merck, Inari, and Truvic. Dr Wang has received research grants to the Duke Clinical Research Institute from Abbott, AstraZeneca, Bristol Myers Squibb, Boston Scientific, Artivion (formerly Cryolife), Chiesi, Merck, Portola, and Regeneron; and has received consulting honoraria from AstraZeneca, Bristol Myers Squibb, Artivion (formerly Cryolife), CSL Behring, and Novartis. Dr Curtis has an institutional contract with the American College of Cardiology for his role as chief scientific adviser of the NCDR; and has equity in Medtronic. Dr Spertus has provided consultative services on patient-reported outcomes and evidence evaluation to Alnylam, AstraZeneca, Bayer, Merck, Janssen, Bristol Meyers Squibb, Edwards Lifesciences, Kineksia, 4DT Medical, Terumo, Cytokinetics, Imbria, and United Healthcare; holds research grants from Bristol Meyers Squibb, Abbott Vascular, and Janssen; owns the copyright to the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and Peripheral Artery Questionnaire; and serves on the Board of Directors for Blue Cross Blue Shield of Kansas City. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu